Autonomic Neuropathy: Diagnosis and Management

Introduction

Autonomic neuropathy is damage to the nerves that regulate involuntary physiological functions - heart rate and blood pressure control, gastrointestinal motility, bladder and sexual function, sweating, and pupillary responses. Because the autonomic nervous system touches almost every organ system, its dysfunction can present in a bewildering variety of ways, which makes recognising the underlying pattern (rather than chasing each symptom individually) the key clinical skill.¹

It most commonly occurs as a component of diabetic neuropathy, developing alongside the more familiar sensory 'glove and stocking' polyneuropathy after years of poorly controlled diabetes, though it also occurs in other neurodegenerative and neuropathic conditions. Like the somatic neuropathy it accompanies, it is length-dependent, which is why the vagus nerve - the longest autonomic nerve in the body - tends to be affected earliest. Loss of vagal parasympathetic tone before sympathetic tone explains the characteristic early finding of a resting tachycardia with reduced heart rate variability, long before postural hypotension appears. It is a compact but high-yield topic because it explains several otherwise puzzling clinical phenomena - falls on standing, silent myocardial ischaemia, unpredictable glycaemic control - that are frequently tested.

The autonomic nervous system has two divisions with opposing effects, and they fail at different rates. Parasympathetic (largely vagal) fibres are the longest and are damaged earliest, which is why loss of heart rate variability and a resting tachycardia precede the sympathetic failure that produces postural hypotension. This sequence is clinically useful: a patient with a fixed, mildly elevated resting heart rate may already have significant cardiac autonomic neuropathy years before they ever feel dizzy on standing.

It also explains why autonomic neuropathy is so often missed. The early features - a slightly fast pulse, constipation, erectile dysfunction - are individually unremarkable and easily attributed to something else, while the dramatic presentations such as syncope or gastroparesis appear only once denervation is advanced. Actively asking about these symptoms in anyone with long-standing diabetes, rather than waiting for them to be volunteered, is what brings the diagnosis forward.

It is worth distinguishing autonomic neuropathy from autonomic failure of central origin, because the implications differ. In diabetes and other peripheral causes, the lesion is in the postganglionic autonomic nerves themselves. In multiple system atrophy and related synucleinopathies, the lesion is central, within the brainstem and spinal cord autonomic nuclei. The clinical picture can look similar at the bedside, but the central causes progress faster, respond less well to treatment, and are accompanied by parkinsonian or cerebellar signs that should be actively sought.

Prevalence in diabetes is substantial and increases with disease duration, though estimates vary widely because case definitions differ and because early disease is asymptomatic. What is consistent is that cardiac autonomic neuropathy is an independent predictor of mortality, over and above the other microvascular complications - which is a strong argument for looking for it deliberately, with a lying and standing blood pressure and an assessment of resting heart rate, rather than waiting for it to declare itself.

Aetiology

• Diabetes mellitus - by far the commonest cause, usually developing after many years of disease, particularly with poor glycaemic control, and typically alongside somatic peripheral neuropathy
• Parkinson's disease and other synucleinopathies - autonomic dysfunction is intrinsic to the underlying neurodegeneration, not simply a treatment side effect
• Multiple system atrophy - autonomic failure is a defining, often early and prominent feature (see Parkinson's disease and Parkinsonism)
• Guillain-Barre syndrome - acute autonomic instability can accompany the motor and sensory features
• Amyloidosis - both hereditary (transthyretin) and acquired (AL) amyloid can cause a severe autonomic neuropathy
• Chronic alcohol excess
• Paraneoplastic autonomic neuropathy
• Drugs - many antihypertensives, tricyclic antidepressants and other agents can cause or unmask autonomic symptoms, particularly postural hypotension
• Pure autonomic failure - a rare, isolated, slowly progressive autonomic synucleinopathy without other neurological features

Clinical features

Features are best understood system by system, since patients rarely present describing 'autonomic neuropathy' - they present with one or more of the following, and recognising the underlying thread is the diagnostic task.³

A useful clinical habit is to ask, in any patient with unexplained symptoms in one of these systems, whether there are symptoms in the others. Isolated erectile dysfunction has a long differential; erectile dysfunction together with postural dizziness, early satiety and reduced sweating in the feet is a single diagnosis. Because the autonomic nervous system is the common thread, the diagnostic yield comes from deliberately crossing system boundaries during the history rather than investigating each complaint in isolation.

A simple bedside battery is available where formal autonomic testing is not. Heart rate variation with deep breathing, the heart rate response to standing, and the blood pressure response to sustained handgrip together give a reasonable assessment of both parasympathetic and sympathetic function, and can be performed in a clinic room with an ECG and a sphygmomanometer.

Cardiovascular

• Postural (orthostatic) hypotension - dizziness, presyncope or syncope on standing, from failure of the normal compensatory vasoconstriction and tachycardia
• Fixed heart rate - loss of normal heart rate variability with respiration, exertion or standing (a resting tachycardia with little further rise on exertion is characteristic)
• Silent myocardial ischaemia - cardiac autonomic denervation can blunt or abolish anginal pain, so myocardial infarction may present atypically (breathlessness, fatigue) or without symptoms at all

Gastrointestinal

• Gastroparesis - delayed gastric emptying causing early satiety, bloating, nausea and vomiting, and importantly erratic and unpredictable blood glucose control in diabetic patients, since food absorption no longer matches the timing of insulin action
• Oesophageal dysmotility - dysphagia and reflux
• Constipation - common, from reduced colonic motility
• Diabetic diarrhoea - episodic, often nocturnal, sometimes alternating with constipation

Genitourinary

• Erectile dysfunction - often an early symptom in diabetic autonomic neuropathy
• Bladder dysfunction - incomplete emptying, overflow incontinence, and recurrent urinary tract infections from an atonic, poorly sensate bladder

Sudomotor and other

• Abnormal sweating - reduced sweating distally (contributing to dry, cracked skin and higher infection risk in diabetic feet) with compensatory increased sweating more proximally (truncal or facial), and gustatory sweating (sweating triggered by eating) in some diabetic patients
• Pupillary abnormalities - reduced pupillary light response
• Impaired hypoglycaemia awareness - in diabetic patients, autonomic neuropathy blunts the adrenergic warning symptoms (tremor, palpitations, sweating) of hypoglycaemia, leaving only neuroglycopenic symptoms (confusion) to warn the patient - a dangerous and important complication

Clinical examination

• Lying and standing blood pressure and heart rate - a fall in systolic blood pressure of 20 mmHg or more (or diastolic 10 mmHg or more) on standing, without an appropriate compensatory rise in heart rate, supports autonomic (rather than purely volume-related) postural hypotension
• Abdominal examination - for a succussion splash or distension suggesting gastroparesis
• Bladder - palpable bladder suggesting retention
• Skin - dryness, cracking, and evidence of reduced sweating distally, especially in the feet
• Pupillary responses
• Full assessment for coexisting somatic peripheral neuropathy - since the two frequently coexist and share causes

Differential diagnosis

• Volume depletion or medication-induced postural hypotension - diuretics, antihypertensives, and dehydration can cause postural symptoms without true autonomic failure; heart rate typically rises appropriately in these cases, unlike in autonomic neuropathy
• Cardiac causes of syncope - arrhythmia or structural heart disease should be excluded, particularly with ECG
• Addison's disease - postural hypotension with hyperpigmentation, hyperkalaemia and hyponatraemia
• Multiple system atrophy - autonomic failure combined with parkinsonism and/or cerebellar signs
• Pure autonomic failure - isolated, slowly progressive autonomic dysfunction without other neurological features, a diagnosis of exclusion

Investigations

• Lying and standing blood pressure - the key bedside test, performed after lying for several minutes and repeated at 1 and 3 minutes after standing
• HbA1c/fasting glucose - to identify or assess control of underlying diabetes
• ECG - assessing heart rate variability and excluding arrhythmia as an alternative cause of symptoms
• Formal autonomic function testing (heart rate response to deep breathing and Valsalva manoeuvre, tilt-table testing) - in specialist settings when the diagnosis is unclear or the pattern of autonomic failure needs formal characterisation
• Gastric emptying studies - if gastroparesis is suspected and confirmation would change management
• Urodynamic studies - for significant bladder dysfunction
• Screen for other causes - B12, TFTs, serum protein electrophoresis, and specific tests for amyloidosis or paraneoplastic antibodies where clinically indicated

Management

Postural hypotension

• Non-pharmacological measures first: adequate hydration and salt intake (where not otherwise contraindicated), avoiding rapid postural change, compression stockings, raising the head of the bed at night, and reviewing and stopping or reducing causative drugs (antihypertensives, diuretics, tricyclics) where possible
• Fludrocortisone - a mineralocorticoid that expands plasma volume, used if non-pharmacological measures are insufficient; monitor for fluid overload and hypokalaemia
• Midodrine - an alpha-agonist that causes vasoconstriction, used as an alternative or adjunct; avoid dosing too close to bedtime because of supine hypertension

Gastrointestinal symptoms

• Dietary modification - smaller, more frequent, lower-fat and lower-fibre meals for gastroparesis
• Prokinetic agents (for example metoclopramide or domperidone) for gastroparesis, used with attention to their own side-effect profiles, particularly extrapyramidal effects with metoclopramide in prolonged use
• Laxatives or antimotility agents as appropriate for constipation or diarrhoea

Genitourinary symptoms

• Phosphodiesterase-5 inhibitors for erectile dysfunction, where not contraindicated
• Intermittent self-catheterisation for significant bladder retention
• Treat recurrent urinary tract infections promptly, and investigate for an underlying incomplete emptying pattern

General

• Optimise glycaemic control in diabetic autonomic neuropathy, though established autonomic damage does not reliably reverse
• Hypoglycaemia awareness education and adjusted glycaemic targets in patients with impaired warning symptoms
• Cardiovascular risk factor management, given the association between cardiac autonomic neuropathy and silent ischaemia/increased cardiovascular mortality

Complications

• Falls and injury from postural hypotension
• Silent myocardial ischaemia and increased cardiovascular mortality
• Severe, unpredictable glycaemic swings from gastroparesis
• Recurrent urinary tract infections and, in severe cases, renal impairment from chronic retention
• Severe, unrecognised hypoglycaemia from impaired awareness
• Significant impact on quality of life from erectile dysfunction, bowel and bladder symptoms

Red flags

Autonomic neuropathy rarely presents as an emergency in itself, but it changes how other presentations should be interpreted - masking the usual warning signs of both cardiac ischaemia and hypoglycaemia. The situations below are where that masking matters most.

Prognosis

Diabetic autonomic neuropathy is generally slowly progressive and does not reverse with glycaemic control once established, though good control slows further progression. It is associated with increased cardiovascular mortality, partly through silent ischaemia and partly reflecting the severity of the underlying microvascular disease.² Autonomic failure in the context of multiple system atrophy or other neurodegenerative synucleinopathies tends to progress faster and carries a worse overall prognosis than isolated diabetic autonomic neuropathy.

Practically, the identification of cardiac autonomic neuropathy should change several things about a patient's care. It raises the threshold for suspecting silent ischaemia, so chest symptoms that would otherwise seem atypical warrant investigation. It calls for caution with drugs that worsen postural hypotension, and for a review of glycaemic targets where hypoglycaemia awareness is impaired. It also warrants a pre-operative discussion, since these patients tolerate anaesthetic-induced vasodilatation and blood loss poorly, and are at higher risk of intraoperative cardiovascular instability.

Patients should be given practical advice for daily life: rising slowly in stages, avoiding large carbohydrate-heavy meals and hot baths that exacerbate postural symptoms, maintaining hydration, and using compression garments where tolerated.

Prevention remains more effective than treatment. In type 1 diabetes in particular, intensive glycaemic control from early in the disease substantially reduces the subsequent development of autonomic neuropathy, whereas tightening control once autonomic damage is established achieves far less. This is the same principle of metabolic legacy seen with the other microvascular complications, and it is a strong argument for good control early rather than reactively.